Breaking News

0 2100
MannKind Corporation MNKD Stock News

MannKind Corporation (NASDAQ: MNKD) is having an incredibly strong day in the market today, and for good reason. One Drop | Plus has been launched. Of course, we’ll get into why that’s a big deal in a minute. Nonetheless, this launch led to excitement among investors who pushed the stock upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (12:17), MNKD is trading at $1.32 per share after a gain of $0.19 per share (17.12%) thus far today.





MNKD Gains On Global One Drop Launch

One Drop is becoming a leader in diabetes management, and it’s happening quickly, ultimately benefiting not only the company, but MannKind as well. So far, the digital diabetes management platform has 200,000 users worldwide, and that number is expanding quickly.

Today, MNKD investors were excited to learn of the launch of One Drop | Plus. This is helping One Drop expand its offering in order to better meet the individual needs of people that struggle with pre-, type 1 and type 2 diabetes. The new product is now available in the United States and Europe.




This is overwhelmingly positive news for MNKD, as the company announced a planned collaboration with One Drop earlier this month. This collaboration will provide cost savings and customized coaching content and will lead to innovation with regard to packaging and exploration of a reusable Afrezza inhaler with integrated Bluetooth technology. So, the launch of yet another likely popular One Drop product means that Afrezza will be seen by more and more consumers. With regard to the launch, Jeff Dachis, CEO and Founder of One Drop, had the following to offer:

At One Drop, we are bringing evidence-based diabetes care into the 21st century with seamlessly integrated devices, a fully featured diabetes management app, data-driven insights, and ongoing one-on-one support from dedicated diabetes experts (likely including MNKD experts) – all right on your mobile phone… No one wants more ‘business as usual’ with yet another clunky device in a vinyl zippered case, expensive supplies, or impersonal, reactive, remote diabetes monitoring from a call center. People deserve much better.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNKD. In particular, we’re interested in following the coming collaboration with One Drop and how this collaboration turns into a profitable opportunity for the company. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Sorl Auto Parts, Inc. SORL Stock News

Sorl Auto Parts, Inc. (NASDAQ: SORL) is having an incredibly strong day in the mSarket today, and for good reason. The stock was featured in Zacks highlights with an incredibly high rank. This led to excitement among investors, sending the stock skyward and prompting an alert from our friends at Trade Ideas. At the moment (12:04), SORL is trading at $9.12 per share after a gain of $1.99 per share or 27.91% thus far today.





Zacks Highlights SORL

As mentioned above, SORL Auto Parts is having a strong day in the market after Zacks made the decision to inform investors of the stock in a feature. In their feature, Zacks pointed out several stocks that could be strong buying opportunities.




In the snippet with regard to SORL, Zacks pointed out that it has ranked the stock a #1, reminding investors that the stock has delivered an average positive earnings surprise of 94.5% over the past 4 quarters. Here’s the highlight that Zacks offered…

SORL Auto Parts, Inc. (NASDAQ: SORL – Free Report ) specializes in the development, production and distribution of air brake valves and hydraulic brake valves. This Zacks Rank #1 stock delivered an average positive earnings surprise of 94.5% in the trailing four quarters.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SORL. In particular, we’re interested in seeing if the company can continue the trend of positive earnings surprises that we have seen throughout the past year. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1982
Advanced Micro Devices, Inc. AMD Stock News

Advanced Micro Devices, Inc. (NASDAQ: AMD) is having yet another rough day in the market today, and for good reason. Recently, there was news of a potential deal with Intel (NASDA: INTC), which sent the stock skyward. However, hopes of the deal seem to be fading. As a result, the stock continues to fall, causing our partners at Trade Ideas to alert us to the declines. At the moment (11:50), AMD is trading at $10.97 per share after a loss of $0.44 per share (3.86%) thus far today.





AMD Falls As Hopes Of INTC Deal Fade

As mentioned above, Advanced Micro Devices is having a rough day in the market today after more and more experts weigh in on the potential deal between the company and Intel. You see, recently, stories broke that INTC would be striking a deal to license AMD GPU technology. However, more and more experts are coming out with opinions that the deal will not happen.




In fact, most recently, Citi Analyst Christopher Danely said that he doesn’t think that the deal will take place. Simply put, Danely said that he doesn’t see a compelling need for Intel to look to AMD for their technology. While neither company involved in the reported potential deal are speaking up as of yet, Danely makes a strong point here, and the idea that the deal won’t take place is concerning investors.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMD. In particular, we’re interested in learning whether or not the company will be able to strike the deal with INTC, as unlikely as it may seem at this point. Also, we’re interested in following the Ryzen story. If things go well there, we could see gains in the future. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Northern Dynasty Minerals Ltd NAK Stock News

Northern Dynasty Minerals Ltd (NYSEMKT: NAK) is having a relatively strong day in the market today as investors weigh the risk-versus-reward aspects associated with the Pebble Project. At the end of the day, the project could prove to be a massive profit, or massive flop for that matter. Today, we’ll put the Pebble story into perspective for those interested in investing in NAK. With the data at hand here, this could prove to be a very strong long-run play.





Breaking Down The NAK Settlement With The EPA

For some time now, Northern Dynasty Minerals has been working to get the Pebble Project rolling. However, there has been one major thorn in the side of the company. That thorn has the letters E.P.A. written all over it! You see, the United States Environmental Protection agency has been working to block progress on Pebble for some time, suggesting that the mine would impact the surrounding environment in a major way, and blocking the company’s ability to even apply for the necessary permits in order to get the project going.

As a result, NAK pursued legal action against the EPA, stating that the agency has violated the legal rights of the company to pursue these permits. Well, that lit a bit of a fire under the EPA, and recently, the two parties reached a settlement that would allow NAK to apply for the permits required to move forward with the mine.




Northern Dynasty Minerals Has Deadlines, But Is Not Concerned

At the end of the day, the bulls and the bears have been fighting about limits associated with the Pebble Project since the settlement. In particular, the biggest limitation the company faces in the process is time. In fact, under the settlement that was recently reached between NAK and the EPA, the company has key deadlines that it must meet. First off, the company must file permit applications by no later than 30 months from the date of the settlement. On top of that, within 48 months, the company must provide a final environmental impact statement that will be filed by the US Army Corps of Engineers.

Nonetheless, NAK doesn’t seem to be concerned about these deadlines in the least. In fact, they don’t intend on taking more than 30 months, or even a full 12 months, to file the permits. The company said this will be done by the end of 2017. On the environmental impact statement side of the coin, that’s expected to come into play by no later than May of 2021, once again, falling cleanly into the deadlines set through the agreement.

Why This Mine Is Such A Big Deal

At first glance, you may think of Northern Dynasty Minerals’ Pebble Project as just another mine. However, the truth of the matter is that this mine has massive potential. In fact, it is expected that there are 56.8 billion pounds of copper in the mine. This, in combination with 70.4 million ounces of gold, 3.4 billion pounds of molybdenum, and 343.6 million ounces of silver will make this one of the most valuable mines in the world!

In particular, the big key here is gold and copper. At the moment, it’s becoming harder and harder to find stored deposits of copper and gold. This mine just so happens to be one of the biggest stored deposits of these two metals in the world. So, as supplies of these commodities dry up because they are becoming more difficult to find, NAK is sitting on top of, for lack of a better phrase, an incredible gold mine!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on Northern Dynasty Minerals. In particular, we’ll be watching the Pebble Project, as the company finally has the green light it needed in order to move forward. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Cumulus Media Inc CMLS Stock News

Cumulus Media Inc (NASDAQ: CMLS) is having an overwhelmingly strong start to the trading session today, and for good reason. Over the weekend, rumors broke that the company would soon be acquired. Interestingly enough, unlike most rumors, there’s strong evidence of this being a real possibility here. As a result, investors pushed the stock upward in a big way, prompting our partners at Trade Ideas to alert us to the gains. At the moment (11:02), CMLS is trading at $0.64 per share after a gain of $0.15 per share (29.82%) thus far today.





CMLS Gains On Buyout Hopes

As mentioned above, Cumulus Media is having an overwhelmingly strong day in the market today as rumors surfaced over the weekend that the company may soon be acquired. The rumor is that Lew Dickey, the former CEO of the company,  is working on a deal to buy the company, and this isn’t one of those rumors that has a very small chance of being true. In fact, there’s strong evidence of a play here.




Recently, Lew Dickey raised $207 million from the public, stating that he was working on a deal. The money was raised through Dikey’s newly formed company, Modern Media Acquisition Corp. In a statement, Dickey made it clear that he does indeed intend to move forward with acquisitions. Here’s what the former CMLS CEO to offer:

Demand was strong… I’m now hard at work looking for a company in media, entertainment or marketing services [with a] value approaching $1 billion. It will be a ‘platform company’ where we expect to make follow-on acquisitions and will be listed on NASDAQ.”

Nonetheless, Dickey didn’t say anything about a planned buyout of Cumulus Media. As a result, it’s important to treat the current gains as rumor-based gains and understand the risk that is associated with acquisition rumors in the market if you’re going to trade on this news.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CMLS. In particular, we’re interested in learning whether or not Dickey will be making a play to acquire the company. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Oclaro, Inc. OCLR Stock News

Oclaro, Inc. (NASDAQ: OCLR) is having an incredibly strong day in the market today, and for good reason. Ultimately, it all boils down to the China mobile build-out and what it means for the company. Of course, positive news led to excitement among investors who pushed the stock upward. This led to an alert from our partners at Trade Ideas. At the moment (10:44), OCLR is trading at $9.32 per share after a gain of $0.82 per share (9.65%) thus far today.





OCLR Gains On China Mobile Build-Out

As mentioend above, Oclaro is having an incredibly strong day in the market after an analyst has pointed out the benefit of China’s mobile build-out to the company. In particular, we’re seeing a build out of the Packet Transport Network, 70% of which is going to ZTE with 30% going to Huawei.




This is overwhelmingly positive news for OCLR, as the company has significant exposure to ZTE. That’s because the company is a major supplier to ZTE. So, if ZTE sees strong sales as a result of the mobile build-out in China, OCLR will also see stronger sales.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on OCLR. In particular, we’re interested in following the China mobile build-out and watching to see what this means for ZTE sales, and Oclaro sales as a result. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 538
Amyris Inc AMRS Stock News

Amyris Inc (NASDAQ: AMRS) is having a strong start in the trading session today, and for good reason. The company announced that it has exceeded its debt reduction goal in a big way. As a result, investor excitement ensued, leading to gains in the value of the stock. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:23), AMRS is trading at $0.30 per share after a gain of $0.01 per share (4.22%) thus far today.





AMRS Gains On Debt Reduction

As mentioned above, Amyris is off to a relatively strong day in the market today after announcing that it has exceeded its debt reduction goal. On May 8th, the company announced that it intended to reduce debt by around $75 million. Well, here we are, couple of weeks later, and the company has already exceeded that goal. In fact, AMRS said it has already retired $86 million in debt. In a statement, John Melo, CEO and President at AMRS, had the following to offer:




We are pleased to have already exceeded our previously stated goal of reducing our debt by approximately $75 million and to have done so in such a short time… We continue to lead the industry in revenue growth and product sales and are very pleased with the continued expansion of collaborations that provide us with a strong and sustainable product pipeline and commercial execution that we expect will continue delivering very strong product revenue. Our continued operational performance combined with strong cash position and much improved balance sheet enable us to deliver on our growth plan.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMRS. In particular, we’re interested in following the company’s continued debt reduction work as well as work on collaborations that we believe will lead to more profitable products ahead. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 749
Puma Biotechnology Inc PBYI Stock News

Puma Biotechnology Inc (NASDAQ: PBYI) is having an overwhelmingly strong start to the trading session this morning. So strong, in fact, that the stock has already seen 2 volatility halts. The gains are ultimately the result of the FDA review of neratinib, which seems to support the potential approval of the treatment. As a result, investors became excited, sending the stock skyward and prompting our partners at Trade Ideas to alert us to the gains. At the moment (9:58), PBYI is trading at $55.00 per share after a gain of $17.20 per share (45.50%) thus far today.





PBYI Gains On FDA Review

As mentioned above, the FDA recently reviewed Puma Biotechnology’s neratinib. Today, the results of that review were released, which proved to be overwhelmingly positive. In the review, the FDA waged no serious concerns, nor dropped any major landmines.

In fact, in the review, the FDA pretty much concluded that the efficacy of the treatment supported the its potential approval. In a key paragraph from the review text, the FDA had the following to offer with regard to PBYI neratinib:




The applicant conducted a multicenter, randomized, double-blind, placebo-controlled study of neratinib versus placebo in women with early-stage HER2-overexpressed/amplified breast cancer after adjuvant treatment with trastuzumab. There were several major unplanned amendments made to the trial impacting enrollment, the number of iDFS events observed, and the period of patient follow up. The primary analysis showed an improvement with neratinib with an absolute difference in iDFS of 2.8% after a 2-year follow-up [stratified HR: 0.66 (0.49, 0.90); p value: 0.008 ]. Despite the unplanned amendments and potential uncertainty introduced with respect to the magnitude of neratinib effect, based on the sensitivity analyses conducted, the results appear to be generally similar to the primary analysis results, supporting an effect of neratinib. The tolerability of neratinib in this patient population is a concern given the frequent dose interruptions, reductions, and discontinuations observed, mostly due to diarrhea. In Study 3004, nearly all patients experienced any Grade diarrhea and 40% of patients experienced Grade 3 diarrhea. Results from the ongoing Phase 2 Study 6201 suggest that antidiarrheal prophylaxis decreases the incidence and severity of diarrhea.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PBYI. In particular, we’re interested in the ongoing application surrounding bringing neratinib to the market, one which seems as though it’s going overwhelmingly well. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 3372
BlackBerry Ltd BBRY Stock News

BlackBerry Ltd (NASDAQ: BBRY) is having a relatively strong start to the trading session this morning, and for good reason. The company announced that it has signed a deal with Ford Motor Company (NYSE: F). This sparked excitement among investors, leading to gains in the stock and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:37), BBRY is trading at $10.52 per share after a gain of $0.14 per share (1.35%) thus far today.





BBRY Signs Agreement With Ford

As mentioned above, BlackBerry is having a strong start to the trading session after news broke that the company has signed an agreement to work directly with Ford. The agreement surrounds the expansion of the QNX secure operating system used by Ford. While full details with regard to the deal are being kept quiet, it is expected that the deal surrounds Ford’s efforts with regard to developing its first autonomous vehicle. This is overwhelmingly positive news for BBRY, as this is the first time the company has worked directly with a major auto manufacturer.




While the rumor surfacing says that this has to do with an autonomous vehicle, it could ultimately surround just about any working technology in Ford vehicles – even the audio system. After all, Panasonic Automotive uses the QNX software for its SYNC 3 infotainment console, the same console that it supplies directly to Ford. In a statement, John Wall, head of the BBRY QNX unit, had the following to offer:

We can form the basis of the entire vehicle all the way from autonomous drive through infotainment…”

The statement above is evidence pertaining to the idea that the deal surrounds the development of autonomous vehicles – something that Ford said it is expecting to produce by the year 2021.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both BBRY and Ford. In particular, we’re interested in learning more about what the result of this deal will be. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 254
Biocept Inc BIOC Stock News

Biocept Inc (NASDAQ: BIOC) is having an incredibly strong time in the pre-market trading hours this morning, and for good reason. The company has been awarded a new patent. Of course, this caused excitement among investors who pushed the stock upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:04), BIOC is trading at $1.73 per share after a gain of $0.30 per share or 20.98% thus far today.




BIOC Receives New Patent

As mentioned above, Biocept is having a strong time in the pre-market hours this morning after announcing that it has been awarded yet another patent. The patent, number 9671407 surrounds the broad use of antibodies for the capture of any target of interest on any solid surface from a sample type. The title of the patent is DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. In particular, the targets of interest are primarily circulating tumor cells, sub-cellular vesicles, and exosomes shed by solid tumors that are found in the blood stream.




This is incredible news as this new patent expands intellectual property protection by BIOC in a big way. In fact, as a result of the issuance of the new patent, the company now has 20 patents in the United States and key international territories. In a statement, Michael Nail, President and CEO at BIOC, had the following to offer…

Obtaining new intellectual property distinguishes our platform’s unique and novel features and, in this case, we believe it offers the potential to drive additional value given the broad implications of this patent. We continue to execute on our business plan, as we leverage our proprietary liquid biopsy technology to help physicians obtain actionable biomarker information to improve treatment pathways and patient outcomes.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching BIOC incredibly closely. In particular, we’re interested in learning the company’s plans surrounding this particular patent. With the broad coverage offered under this patent, the company could use this property as a licensing tool, which could get very interesting. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5140
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...